I2Pure Corp

I2Pure has developed a platform that delivers pure molecular iodine in topicals, medical devices and implant coatings. I2Pure will impact every clinical practice that is in contact with human tissue.

I2Pure will have three products and registered within the US in 2023. (Skin prep, Dermal regeneration matrix and a wound irrigation system.) Partnership with Magle Chemoswed to produce a hemostat, hydro-gel, and a gel. Developing 7 products for Becton Dickenson and 1 product for Conmed. Will start an IRB with Foley Catheters with UCSD in 2023. 3 human trials to begin this year. (Burn care at the U of Ghent, Diabetic Foot Ulcers in three Hospitals in India, and a chronic wound study in the Caribbean.) Working with 10+ world class institutions in development and research collaborations.

Every indication of medical practice that comes into contact with human tissue is at risk for causing infection. Indwelling devices cause infection. Implants and surgical repairs cause infection. Skin infections and disease are becoming resistant to treatment. Chronic wounds are increasing in occurrence. Pathogens are winning the war against their human hosts.

I2Pure can deliver high concentrations of molecular iodine in many formats. I2Pure is not only thousands of times more powerful than the iodine that is used in the hospital today, it is non-toxic, non-staining, persistent, anti-inflammatory and highly compatible with human tissue.

I2Pure will manufacture molecular iodine. Will license technology for specific indications and geography, and will take ownership in partners where appropriate.

GSD